Opus Genetics, Inc. (IRD)
5.11
-0.15
(-2.85%)
USD |
NASDAQ |
May 07, 10:49
Opus Genetics Cash from Investing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Keros Therapeutics, Inc. | -0.134M |
| Moderna, Inc. | -76.00M |
| ACADIA Pharmaceuticals, Inc. | -55.87M |
| Alnylam Pharmaceuticals, Inc. | -25.54M |
| Savara, Inc. | -93.56M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -9.833M |
| Cash from Financing (Quarterly) | 24.11M |
| Free Cash Flow | -35.25M |
| Free Cash Flow Per Share (Quarterly) | -0.1407 |
| Free Cash Flow to Equity (Quarterly) | -9.894M |
| Free Cash Flow to Firm (Quarterly) | -9.772M |
| Free Cash Flow Yield | -11.60% |